H. Klei

发表

Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation

W. Metzler, J. Yanchunas, C. Weigelt, 2008, Protein science : a publication of the Protein Society.

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Ping Chen, A. Doweyko, Derek J. Norris, 2004, Journal of medicinal chemistry.

Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.

J. Yanchunas, K. Kish, H. Klei, 2009, Bioorganic & medicinal chemistry letters.

The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.

H. Klei, N. Meanwell, R. Rajamani, 2018, Bioorganic & medicinal chemistry letters.

Molecular, biological, and preliminary structural analysis of recombinant bryodin 1, a ribosome-inactivating protein from the plant Bryonia dioica.

H. Klei, H. Einspahr, S. Gawlak, 1997, Biochemistry.

The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor.

J. Tokarski, K. Kish, H. Klei, 2004 .

Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.

L. Mueller, K. Kish, H. Klei, 2016, Journal of medicinal chemistry.

7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.

Wei Wang, C. Weigelt, K. Kish, 2011, Bioorganic & medicinal chemistry letters.

Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.

S. Chong, J. Yanchunas, K. Kish, 2009, Bioorganic & medicinal chemistry letters.

Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.

Ying Wang, Doree Sitkoff, Jing Zhang, 2011, Bioorganic & medicinal chemistry letters.

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.

Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).

C. Weigelt, K. Kish, H. Klei, 2013, Journal of medicinal chemistry.

Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.

C. Weigelt, K. Kish, H. Klei, 2010, Journal of medicinal chemistry.

The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.

Qi Gao, Huabin Sun, Hong Shi, 2014, Journal of medicinal chemistry.

Structural basis for CARM1 inhibition by indole and pyrazole inhibitors.

K. Kish, H. Klei, D. Xie, 2011, The Biochemical journal.

Automating crystallographic structure solution and refinement of protein–ligand complexes

R. Read, P. Adams, T. Terwilliger, 2013, Acta crystallographica. Section D, Biological crystallography.

Ligand placement based on prior structures: the guided ligand-replacement method

Paul D. Adams, Nathaniel Echols, Nigel W. Moriarty, 2013, Acta crystallographica. Section D, Biological crystallography.

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

M. Wittekind, J. Tokarski, K. Kish, 2006, Cancer research.

High Resolution Crystal Structure of Human β-Glucuronidase Reveals Structural Basis of Lysosome Targeting

W. Sly, H. Klei, A. Waheed, 2013, PloS one.

Interactive comparison and remediation of collections of macromolecular structures

Nathaniel Echols, Paul D Adams, Dorothee Liebschner, 2018, Protein science : a publication of the Protein Society.

Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor.

A. Good, K. Kish, H. Klei, 2018, ACS medicinal chemistry letters.

X-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with Atazanavir

Steven Sheriff, Kevin Kish, Ronald E. Rose, 2007, Journal of Virology.

Purification and preliminary crystallographic studies of penicillin G acylase from Providencia rettgeri

H. Klei, J. A. Kelly, G. Daumy, 1995, Protein science : a publication of the Protein Society.

Crystal structure of penicillin G acylase from the bro1 mutant strain of providencia rettgeri

H. Klei, M. McDonough, J. A. Kelly, 1999, Protein science : a publication of the Protein Society.

Automated ligand fitting by core-fragment fitting and extension into density

Judith D. Cohn, Paul D. Adams, Nigel W. Moriarty, 2006, Acta crystallographica. Section D, Biological crystallography.

Automating crystallographic structure solution and refinement of protein–ligand complexes

R. Read, P. Adams, T. Terwilliger, 2013, Acta crystallographica. Section D, Biological crystallography.

Electronic Reprint Biological Crystallography Automated Ligand Fitting by Core-fragment Fitting and Extension into Density Biological Crystallography Automated Ligand Fitting by Core-fragment Fitting and Extension into Density

P. Adams, T. Terwilliger, H. Klei, 2006 .